Humacyte, Inc.
HUMAW
NASDAQ Global Select0.06
USD
-0.01
- -
CIK
0001818382
ISIN
US44486Q1114
CUSIP
44486Q111
Return %
Stock
S&P500
1Y
-89.62
26.53
3Y
-94.27
76.60
5Y
-97.82
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Laura E. Niklason
- Full Time Employees
- 218
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2525 East North Carolina Highway 54 Durham DE United States of America 27713
- IPO Date
- Dec 1, 2020
- CIK
- 0001818382
- Website
- humacyte.com
- Similar Companies
- Business
- Humacyte, Inc. (Nasdaq: HUMA) develops and manufactures universally implantable, off-the-shelf, bioengineered human tissues and organs primarily for vascular repair, reconstruction, and replacement to treat injuries, diseases, and chronic conditions; its core products and investigational candidates include the FDA-approved Symvess (acellular tissue engineered vessel, or ATEV) for extremity vascular trauma repair, human acellular vessels targeting arteriovenous access for hemodialysis (Phase 3), peripheral artery disease, coronary artery bypass grafting, and pediatric heart surgery, as well as advanced organ systems such as BioVascular Pancreas for Type 1 diabetes and lung applications, plus advanced tissue constructs including urinary conduits, tracheal replacement, and esophageal replacement—all leveraging a proprietary bioengineering platform that decellularizes human tissues to enable host cell repopulation with reduced infection risk and no immunosuppression requirement. Founded in 2004 and headquartered in Durham, North Carolina, the company operates principally in the United States with a focus on regenerative medicine for trauma centers, dialysis patients, military facilities, and cardiovascular indications. Recent developments include U.S. FDA approval of Symvess in December 2024 enabling commercial shipments following batch release authorization, expansion of intellectual property with a new U.S. patent in September 2025 for bioengineered esophagus extending protection to 2041 across the U.S., Europe, Canada, and Australia alongside coverage for trachea and urinary conduits, achievement of primary endpoints in the V007 Phase 3 trial for dialysis AV access, interim cost reductions targeting $50 million in savings with Q3 2025 R&D expenses dropping to $17 million, and plans for sales force expansion plus a supplemental BLA for dialysis in late 2026.